60 related articles for article (PubMed ID: 21248446)
1. Role of cetuximab and sorafenib in treatment of metastatic colorectal cancer.
Galal KM; Khaled Z; Mourad AM
Indian J Cancer; 2011; 48(1):47-54. PubMed ID: 21248446
[TBL] [Abstract][Full Text] [Related]
2. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial.
Siu LL; Shapiro JD; Jonker DJ; Karapetis CS; Zalcberg JR; Simes J; Couture F; Moore MJ; Price TJ; Siddiqui J; Nott LM; Charpentier D; Liauw W; Sawyer MB; Jefford M; Magoski NM; Haydon A; Walters I; Ringash J; Tu D; O'Callaghan CJ
J Clin Oncol; 2013 Jul; 31(19):2477-84. PubMed ID: 23690424
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
[TBL] [Abstract][Full Text] [Related]
4. K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
Karapetis CS; Khambata-Ford S; Jonker DJ; O'Callaghan CJ; Tu D; Tebbutt NC; Simes RJ; Chalchal H; Shapiro JD; Robitaille S; Price TJ; Shepherd L; Au HJ; Langer C; Moore MJ; Zalcberg JR
N Engl J Med; 2008 Oct; 359(17):1757-65. PubMed ID: 18946061
[TBL] [Abstract][Full Text] [Related]
5. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
Khambata-Ford S; Garrett CR; Meropol NJ; Basik M; Harbison CT; Wu S; Wong TW; Huang X; Takimoto CH; Godwin AK; Tan BR; Krishnamurthi SS; Burris HA; Poplin EA; Hidalgo M; Baselga J; Clark EA; Mauro DJ
J Clin Oncol; 2007 Aug; 25(22):3230-7. PubMed ID: 17664471
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.
Lurje G; Nagashima F; Zhang W; Yang D; Chang HM; Gordon MA; El-Khoueiry A; Husain H; Wilson PM; Ladner RD; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ
Clin Cancer Res; 2008 Dec; 14(23):7884-95. PubMed ID: 19047118
[TBL] [Abstract][Full Text] [Related]
7. Magnetic resonance imaging as an early indicator of clinical outcome in patients with metastatic colorectal carcinoma treated with cetuximab or panitumumab.
Ricotta R; Vanzulli A; Moroni M; Colnago B; Oriani M; Nichelatti M; Sarnataro C; Venturini F; Di Bella S; Maiolani M; Giganti MO; Sartore-Bianchi A; Siena S
Clin Colorectal Cancer; 2013 Mar; 12(1):45-53. PubMed ID: 23041354
[TBL] [Abstract][Full Text] [Related]
8. Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers.
Rosa R; Melisi D; Damiano V; Bianco R; Garofalo S; Gelardi T; Agrawal S; Di Nicolantonio F; Scarpa A; Bardelli A; Tortora G
Clin Cancer Res; 2011 Oct; 17(20):6531-41. PubMed ID: 21890455
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.
Baselga J; Segalla JG; Roché H; Del Giglio A; Pinczowski H; Ciruelos EM; Filho SC; Gómez P; Van Eyll B; Bermejo B; Llombart A; Garicochea B; Durán MÁ; Hoff PM; Espié M; de Moraes AA; Ribeiro RA; Mathias C; Gil Gil M; Ojeda B; Morales J; Kwon Ro S; Li S; Costa F
J Clin Oncol; 2012 May; 30(13):1484-91. PubMed ID: 22412143
[TBL] [Abstract][Full Text] [Related]
11. EGFR fluorescence in situ hybridization pattern of chromosome 7 disomy predicts resistance to cetuximab in KRAS wild-type metastatic colorectal cancer patients.
Li YH; Wang F; Shen L; Deng YM; Shao Q; Feng F; An X; Wang FH; Wang ZQ; Xu RH; Shao JY
Clin Cancer Res; 2011 Jan; 17(2):382-90. PubMed ID: 20884623
[TBL] [Abstract][Full Text] [Related]
12. [Two cases of colorectal cancer patients with poor performance status who had unresectable liver metastasis effectively treated by cetuximab].
Osawa G; Yoshimatsu K; Yokomizo H; Matsumoto A; Yano Y; Itagaki H; Otani T; Fujimoto T; Umehara A; Ogawa K
Gan To Kagaku Ryoho; 2010 Nov; 37(11):2189-91. PubMed ID: 21084825
[TBL] [Abstract][Full Text] [Related]
13. [Oncology 2008].
Stemmler HJ; Heinemann V
Dtsch Med Wochenschr; 2008 Jun; 133(25-26):1395-9. PubMed ID: 18521794
[No Abstract] [Full Text] [Related]
14. Role of β4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab.
Scartozzi M; Giampieri R; Loretelli C; Mandolesi A; del Prete M; Biagetti S; Alfonsi S; Faloppi L; Bianconi M; Bittoni A; Bearzi I; Cascinu S
Future Oncol; 2013 Aug; 9(8):1207-14. PubMed ID: 23617461
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab for metastatic colorectal cancer.
Roila F; Garassino MC; Ballatori E
N Engl J Med; 2009 Jul; 361(1):95; author reply 96-7. PubMed ID: 19579279
[No Abstract] [Full Text] [Related]
16. Cetuximab for metastatic colorectal cancer.
Bria E; Cuppone F; Di Maio M
N Engl J Med; 2009 Jul; 361(1):95-6; author reply 96-7. PubMed ID: 19579280
[No Abstract] [Full Text] [Related]
17. Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma.
Hof H; Welzel T; Debus J
Onkologie; 2006 Dec; 29(12):572-4. PubMed ID: 17202828
[TBL] [Abstract][Full Text] [Related]
18. Durable complete remission following anti-EGFR antibodies in recurrent metastatic colorectal cancer.
Boudrias-Dalle E; Cloutier M; Harvey M; Leblanc G; Besner-Morin O; Adam JP
J Oncol Pharm Pract; 2019 Jan; 25(1):239-243. PubMed ID: 28950807
[TBL] [Abstract][Full Text] [Related]
19. Clinical Trial Data for Third-Line Therapy in Metastatic Colorectal Cancer.
Bekaii-Saab T
Clin Adv Hematol Oncol; 2019 Mar; 17 Suppl 7(3):5-13. PubMed ID: 31730590
[No Abstract] [Full Text] [Related]
20. Evaluating the Time Toxicity of Cancer Treatment in the CCTG CO.17 Trial.
Gupta A; O'Callaghan CJ; Zhu L; Jonker DJ; Wong RPW; Colwell B; Moore MJ; Karapetis CS; Tebbutt NC; Shapiro JD; Tu D; Booth CM
JCO Oncol Pract; 2023 Jun; 19(6):e859-e866. PubMed ID: 36881786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]